Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:GSK
|
| gptkbp:activities |
inhibits norepinephrine reuptake
inhibits serotonin reuptake |
| gptkbp:affects |
weight changes
sexual dysfunction increased blood pressure serotonin syndrome risk |
| gptkbp:approves |
gptkb:2004
gptkb:FDA |
| gptkbp:brand |
gptkb:Cymbalta
Yentreve |
| gptkbp:category |
gptkb:C
|
| gptkbp:clinical_trial |
Phase IV
Phase III |
| gptkbp:contraindication |
MAO inhibitors
severe liver impairment uncontrolled narrow-angle glaucoma |
| gptkbp:developed_by |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:dosage_form |
120 mg daily maximum
30 mg to 60 mg daily |
| https://www.w3.org/2000/01/rdf-schema#label |
Duloxetine
|
| gptkbp:ingredients |
C18 H19 NOS
|
| gptkbp:interacts_with |
gptkb:beer
anticoagulants other antidepressants NSAI Ds |
| gptkbp:is_available_on |
gptkb:beer
delayed-release capsule |
| gptkbp:is_used_for |
chronic pain
fibromyalgia generalized anxiety disorder major depressive disorder |
| gptkbp:lifespan |
12 hours
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:metabolism |
liver
|
| gptkbp:side_effect |
dizziness
fatigue nausea insomnia constipation dry mouth sweating |
| gptkbp:symptoms |
dizziness
headache nausea irritability insomnia |
| gptkbp:type_of |
116539-59-4
|